In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma Quarterly Dealmaking Statistics, Q2 2016

A look at financing, M&A and alliance activity April–June 2016

Executive Summary

Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.


Related Content

Spark Therapeutics Now Targets 2017 For US Approval Of First Retinal Gene Therapy
Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017
Hengrui Pursues Innovation Through New $100m US Spinoff
Merck To Get Chronic Cough P2X3 Inhibitor Candidate With Afferent Buy
Was Rova-T Worth The High Price To AbbVie?
Celator Shines At ASCO, Highlights Upside For Jazz
Jazz Singing A Stronger Oncology Tune Through Celator Buy
Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
DalCor To Develop Failed Roche CETP Inhibitor In Genetic Subgroup


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts